A Middle-Aged Beckman Experiences Growing Pains

In the early 1990s, Beckman was hit by adverse market conditions in its two major businesses, life sciences and clinical diagnostics. A strategic restructuring in the past two years has left it in strong financial shape and focused it on new areas of growth.

In the early 1990s, management at Beckman Instruments Inc.viewed the Italian diagnostic market with alarm. Italy was Beckman’s second-largest geographic market and spurred by changes in government reimbursement, testing volume there was declining at a rapid rate. Many of Beckman’s Italian customers were unable to meet minimum volume requirements on reagent sales.

While its European competitors stood by hoping for a turnaround, Beckman management took a hard stance. It pulled its high-volume...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.